Acute kidney injury can occur with checkpoint inhibitors
Avoiding concurrent PPIs may be wise, say researchers
About 3% of cancer patients treated with immune-checkpoint inhibitors develop sustained acute kidney injury potentially due to their therapy, a retrospective study suggests.
US researchers reviewed data on more than 1000 cancer patients who received checkpoint inhibitors between 2011 and 2016 at Massachusetts General Hospital.
